AbbVie Stock Price, News & Analysis (NYSE:ABBV)

$118.60 +3.70 (+3.22 %)
(As of 02/19/2018 11:00 AM ET)
Previous Close$114.90
Today's Range$115.20 - $119.20
52-Week Range$61.17 - $125.86
Volume8.83 million shs
Average Volume7.37 million shs
Market Capitalization$189.34 billion
P/E Ratio28.79
Dividend Yield2.47%
Beta1.61

About AbbVie (NYSE:ABBV)

AbbVie logoAbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty & Advanced Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNYSE:ABBV
CUSIP00287Y10
Phone+1-847-9327900

Debt

Debt-to-Equity Ratio5.08%
Current Ratio1.45%
Quick Ratio1.32%

Price-To-Earnings

Trailing P/E Ratio28.7864077669903
Forward P/E Ratio15.90
P/E Growth1.13

Sales & Book Value

Annual Sales$28.22 billion
Price / Sales6.71
Cash Flow$5.59 per share
Price / Cash21.20
Book Value$2.85 per share
Price / Book41.61

Profitability

Trailing EPS$4.12
Net Income$5.31 billion
Net Margins18.82%
Return on Equity152.78%
Return on Assets13.42%

Miscellaneous

Employees30,000
Outstanding Shares1,596,430,000

AbbVie (NYSE:ABBV) Frequently Asked Questions

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Thursday, February 15th. Investors of record on Friday, April 13th will be given a dividend of $0.96 per share on Tuesday, May 15th. This represents a $3.84 dividend on an annualized basis and a yield of 3.24%. The ex-dividend date is Thursday, April 12th. This is a positive change from AbbVie's previous quarterly dividend of $0.71. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie announced that its board has authorized a share repurchase plan on Friday, February 16th 2018, which permits the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to purchase shares of its stock through open market purchases. Shares repurchase plans are generally an indication that the company's management believes its stock is undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) announced its quarterly earnings data on Friday, January, 26th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.44 by $0.04. The company had revenue of $7.74 billion for the quarter, compared to analyst estimates of $7.53 billion. AbbVie had a return on equity of 152.78% and a net margin of 18.82%. The firm's quarterly revenue was up 13.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.20 EPS. View AbbVie's Earnings History.

When will AbbVie make its next earnings announcement?

AbbVie is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for AbbVie.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its first quarter earnings guidance on Friday, January, 26th. The company provided earnings per share (EPS) guidance of $1.77-1.79 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.49. AbbVie also updated its FY18 guidance to $7.33-7.43 EPS.

Where is AbbVie's stock going? Where will AbbVie's stock price be in 2018?

14 brokers have issued 1-year price objectives for AbbVie's shares. Their forecasts range from $88.00 to $157.00. On average, they expect AbbVie's share price to reach $121.15 in the next twelve months. View Analyst Ratings for AbbVie.

What are Wall Street analysts saying about AbbVie stock?

Here are some recent quotes from research analysts about AbbVie stock:

  • 1. According to Zacks Investment Research, "AbbVie’s key drug Humira has been performing well based on strong demand trends for the drug, despite new competition. Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. AbbVie’s shares outperformed the industry in the past one year supported by a series of positive news including promising data from several pivotal studies, regulatory approvals in the U.S., Europe, and Japan for its competitive HCV medicine Mavyret and FDA approval for the sixth indication for Imbrivica and settlement of its Humira patent disputes with Amgen. Also, several pivotal data readouts and regulatory milestones are expected in 2018. However, HCV sales continue to be hurt by intensifying competition. Estimates have gone up slightly ahead of the Q4 earnings release. AbbVie has a positive record of earnings surprises in the recent quarters." (1/22/2018)
  • 2. UBS Group AG analysts commented, "For other pipeline products, we already included appropriate risk-adj estimates and in some cases significant risk adj sales (Rova-T)," (9/25/2017)

Who are some of AbbVie's key competitors?

Who are AbbVie's key executives?

AbbVie's management team includes the folowing people:

  • Richard A. Gonzalez, Chairman of the Board, Chief Executive Officer (Age 63)
  • William J. Chase, Executive Vice President, Chief Financial Officer (Age 49)
  • Michael Severino M.D., Executive Vice President - Research & Development, Chief Scientific Officer (Age 51)
  • Laura J. Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary (Age 53)
  • Carlos Alban, Executive Vice President - Commercial Operations (Age 54)
  • Henry O. Gosebruch, Executive Vice President, Chief Strategy Officer (Age 44)
  • Timothy J. Richmond, Senior Vice President - Human Resources (Age 50)
  • Azita Saleki-Gerhardt Ph.D., Senior Vice President - Operations (Age 53)
  • Robert A. Michael, Vice President, Controller (Age 46)
  • Robert J. Alpern M.D., Independent Director (Age 66)

Who owns AbbVie stock?

AbbVie's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.35%), Bank of New York Mellon Corp (1.05%), Geode Capital Management LLC (1.00%), Orbis Allan Gray Ltd (0.79%), Jennison Associates LLC (0.71%) and TIAA CREF Investment Management LLC (0.65%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Thomas A Hurwich, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Who sold AbbVie stock? Who is selling AbbVie stock?

AbbVie's stock was sold by a variety of institutional investors in the last quarter, including American International Group Inc., Credit Agricole S A, Aristotle Capital Management LLC, Arrowstreet Capital Limited Partnership, Orbis Allan Gray Ltd, Alps Advisors Inc., LSV Asset Management and Metropolitan Life Insurance Co. NY. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Carlos Alban, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

Who bought AbbVie stock? Who is buying AbbVie stock?

AbbVie's stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, BlackRock Inc., Amundi Pioneer Asset Management Inc., Swedbank, SG Americas Securities LLC, Fred Alger Management Inc., Geode Capital Management LLC and Standard Life Aberdeen plc. View Insider Buying and Selling for AbbVie.

How do I buy AbbVie stock?

Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AbbVie's stock price today?

One share of AbbVie stock can currently be purchased for approximately $118.60.

How big of a company is AbbVie?

AbbVie has a market capitalization of $189.34 billion and generates $28.22 billion in revenue each year. The company earns $5.31 billion in net income (profit) each year or $4.12 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

How can I contact AbbVie?

AbbVie's mailing address is 1 N Waukegan Rd, NORTH CHICAGO, IL 60064-1802, United States. The company can be reached via phone at +1-847-9327900.


MarketBeat Community Rating for AbbVie (ABBV)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  666 (Vote Outperform)
Underperform Votes:  401 (Vote Underperform)
Total Votes:  1,067
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AbbVie (NYSE:ABBV) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.432.642.632.57
Ratings Breakdown: 1 Sell Rating(s)
6 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $121.15$100.15$95.60$76.31
Price Target Upside: 5.44% upside1.18% upside1.11% upside8.36% upside

AbbVie (NYSE:ABBV) Consensus Price Target History

Price Target History for AbbVie (NYSE:ABBV)

AbbVie (NYSE:ABBV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/15/2018BMO Capital MarketsReiterated RatingSell$95.00HighView Rating Details
2/15/2018Piper Jaffray CompaniesBoost Price TargetOverweight$130.00 -> $138.00HighView Rating Details
2/2/2018ArgusBoost Price TargetBuy$120.00 -> $145.00LowView Rating Details
1/30/2018Morgan StanleyBoost Price TargetEqual Weight -> Equal Weight$99.00 -> $131.00LowView Rating Details
1/29/2018Evercore ISIReiterated RatingBuy$144.00LowView Rating Details
1/29/2018Credit Suisse GroupSet Price TargetHold$98.00 -> $135.00MediumView Rating Details
1/29/2018SunTrust BanksBoost Price TargetBuy -> Average$157.00LowView Rating Details
1/29/2018Leerink SwannDowngradeOutperform -> Market Perform$127.00MediumView Rating Details
1/4/2018Jefferies GroupBoost Price TargetBuy$115.00 -> $120.00LowView Rating Details
11/21/2017Societe GeneraleBoost Price TargetN/AView Rating Details
10/13/2017BarclaysBoost Price TargetEqual Weight$90.00N/AView Rating Details
10/11/2017CowenUpgradeMarket Perform -> Outperform$91.17 -> $105.00N/AView Rating Details
9/28/2017Deutsche BankBoost Price TargetHold$88.00LowView Rating Details
9/8/2017Goldman Sachs GroupReiterated RatingBuy$85.00 -> $100.00LowView Rating Details
12/8/2016William BlairReiterated RatingOutperform$76.00N/AView Rating Details
11/28/2016CitigroupDowngradeBuy -> Neutral$60.00N/AView Rating Details
9/8/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$75.00 -> $73.00N/AView Rating Details
9/1/2016Raymond James FinancialInitiated CoverageOutperform$82.00N/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

AbbVie (NYSE:ABBV) Earnings History and Estimates Chart

Earnings by Quarter for AbbVie (NYSE:ABBV)

AbbVie (NYSE ABBV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2018$1.68N/AView Earnings Details
1/26/2018Q4 2017$1.44$1.48$7.53 billion$7.74 billionViewListenView Earnings Details
10/27/2017Q3 2017$1.39$1.41$7.00 billion$7.00 billionViewN/AView Earnings Details
7/28/2017Q2 2017$1.40$1.42$6.93 billion$6.94 billionViewN/AView Earnings Details
4/27/2017Q1 2017$1.26$1.28$6.49 billion$6.54 billionViewN/AView Earnings Details
1/27/2017Q416$1.20$1.20$6.92 billion$6.78 billionViewListenView Earnings Details
10/28/2016Q316$1.21$1.21$6.55 billion$6.43 billionViewListenView Earnings Details
7/29/2016Q216$1.20$1.26$6.20 billion$6.43 billionViewListenView Earnings Details
4/28/2016Q116$1.14$1.15$6.03 billion$5.96 billionViewListenView Earnings Details
1/29/2016Q415$1.12$1.13$6.41 billion$6.36 billionViewListenView Earnings Details
10/30/2015Q315$1.08$1.13$5.90 billion$4.94 billionViewListenView Earnings Details
7/24/2015Q215$1.06$1.08$5.60 billion$5.48 billionViewListenView Earnings Details
4/23/2015Q115$0.85$0.94$718.50 million$5.04 billionViewListenView Earnings Details
1/30/2015Q414$0.86$0.89$5.34 billion$5.45 billionViewListenView Earnings Details
10/31/2014Q3$0.77$0.89$4.82 million$5.02 millionViewListenView Earnings Details
7/25/2014Q214$0.76$0.82$4.70 billion$4.93 billionViewListenView Earnings Details
4/25/2014Q114$0.68$0.71$4.33 billion$4.56 billionViewListenView Earnings Details
1/31/2014Q413$0.82$0.82$5.10 billion$5.11 billionViewListenView Earnings Details
10/25/2013Q313$0.78$0.82$4.52 billion$4.66 billionViewListenView Earnings Details
7/26/2013Q2 2013$0.79$0.92$4.54 billion$4.69 billionViewListenView Earnings Details
4/26/2013Q1 2013$0.67$0.68$4.17 billion$4.33 billionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

AbbVie (NYSE:ABBV) Earnings Estimates

2018 EPS Consensus Estimate: $7.58
2019 EPS Consensus Estimate: $8.42
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$1.73$1.80$1.78
Q2 20183$1.82$1.88$1.86
Q3 20183$1.89$1.95$1.92
Q4 20183$1.94$2.08$2.02
Q1 20191$2.06$2.06$2.06
Q2 20191$2.06$2.06$2.06
Q3 20191$2.08$2.08$2.08
Q4 20191$2.22$2.22$2.22
(Earnings estimates data provided by Zacks Investment Research)

Dividends

AbbVie (NYSE:ABBV) Dividend Information

Next Dividend:5/15/2018
Annual Dividend:$2.84
Dividend Yield:2.39%
Dividend Growth:15.50% (3 Year Average)
Payout Ratio:68.93% (Trailing 12 Months of Earnings)
38.07% (Based on This Year's Estimates)
33.14% (Based on Next Year's Estimates)
Track Record:45 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for AbbVie (NYSE:ABBV)

AbbVie (NYSE:ABBV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/15/2018quarterly$0.963.36252189141856%4/12/20184/13/20185/15/2018
10/27/2017Quarterly$0.713.12%1/11/20181/12/20182/15/2018
9/8/2017Quarterly$0.642.94%10/12/201710/13/201711/15/2017
6/23/2017quarterly$0.643.52%7/12/20177/14/20178/15/2017
2/17/2017quarterly$0.644.14%4/11/20174/13/20175/15/2017
10/28/2016quarterly$0.644.44%1/11/20171/13/20172/15/2017
9/12/2016quarterly$0.573.56%10/12/201610/14/201611/15/2016
6/17/2016quarterly$0.573.8%7/13/20167/15/20168/15/2016
2/19/2016quarterly$0.574.2%4/13/20164/15/20165/16/2016
11/2/2015quarterly$0.573.6%1/13/20161/15/20162/16/2016
9/14/2015quarterly$0.513.46%10/13/201510/15/201511/14/2015
6/19/2015quarterly$0.512.94%7/13/20157/15/20158/14/2015
2/20/2015quarterly$0.513.33%4/13/20154/15/20155/15/2015
10/20/2014quarterly$0.493.48%1/13/20151/15/20152/13/2015
9/19/2014quarterly$0.422.86%10/10/201410/15/201411/17/2014
6/19/2014quarterly$0.423.15%7/11/20147/15/20148/15/2014
2/20/2014quarterly$0.423.29%4/11/20144/15/20145/15/2014
12/12/2013quarterly$0.403.06%1/13/20141/15/20142/14/2014
9/19/2013quarterly$0.403.34%10/10/201310/15/201311/15/2013
6/20/2013quarterly$0.403.75%7/11/20137/15/20138/15/2013
2/15/2013quarterly$0.404.19%4/11/20134/15/20135/15/2013
1/7/2013special$0.401/11/20131/15/20132/15/2013
1/4/2013quarterly$0.401/15/20132/15/2013
(Data available from 1/1/2013 forward)

Insider Trades

AbbVie (NYSE ABBV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 69.49%
Insider Trades by Quarter for AbbVie (NYSE:ABBV)
Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

AbbVie (NYSE ABBV) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/18/2017Timothy J RichmondSVPSell87,040$98.45$8,569,088.00113,118View SEC Filing  
12/15/2017Laura J SchumacherInsiderSell145,510$96.71$14,072,272.10View SEC Filing  
11/21/2017Richard A GonzalezChairmanSell218,193$94.01$20,512,323.93492,030View SEC Filing  
11/10/2017Michael SeverinoEVPSell25,633$94.69$2,427,188.77114,922View SEC Filing  
10/30/2017Henry O GosebruchInsiderSell18,300$90.55$1,657,065.0081,287View SEC Filing  
9/28/2017Robert A MichaelVPSell6,699$88.00$589,512.0010,007View SEC Filing  
9/11/2017Azita Saleki-GerhardtSVPSell8,300$85.02$705,666.0093,099View SEC Filing  
8/7/2017Richard A GonzalezChairmanSell193,131$71.00$13,712,301.00469,623View SEC Filing  
8/4/2017Richard A GonzalezChairmanSell87,899$71.02$6,242,586.98342,353View SEC Filing  
8/3/2017Richard A GonzalezCEOSell65,861$71.00$4,676,131.00342,353View SEC Filing  
7/31/2017Edward J RappDirectorBuy4,000$70.45$281,800.0015,498View SEC Filing  
7/31/2017Henry O GosebruchInsiderSell18,000$70.09$1,261,620.0096,074View SEC Filing  
6/14/2017Carlos AlbanEVPSell45,800$70.00$3,206,000.00160,545View SEC Filing  
6/14/2017Laura J SchumacherInsiderSell79,800$70.00$5,586,000.00187,625View SEC Filing  
5/19/2017Richard A GonzalezChairmanSell71,235$65.49$4,665,180.15349,462View SEC Filing  
5/18/2017William J ChaseCFOSell38,300$65.35$2,502,905.00209,043View SEC Filing  
5/4/2017Carlos AlbanEVPSell43,000$67.00$2,881,000.00114,745View SEC Filing  
3/10/2017Laura J SchumacherInsiderSell40,000$65.26$2,610,400.00147,415View SEC Filing  
3/10/2017Robert A MichaelVPSell5,132$65.29$335,068.2816,706View SEC Filing  
3/10/2017Timothy J RichmondSVPSell22,451$65.29$1,465,825.7926,078View SEC Filing  
3/8/2017Richard A GonzalezChairmanSell72,016$64.25$4,627,028.00369,113View SEC Filing  
12/2/2016William J ChaseCFOSell6,600$59.19$390,654.00178,970View SEC Filing  
9/7/2016Laura J SchumacherInsiderSell50,000$65.00$3,250,000.00144,138View SEC Filing  
6/24/2016Laura J SchumacherEVPSell186,106$60.03$11,171,943.18260,438View SEC Filing  
6/2/2016Richard A GonzalezCEOSell285,953$63.82$18,249,520.46624,374View SEC Filing  
5/11/2016Richard A GonzalezCEOSell39,000$63.80$2,488,200.00338,421View SEC Filing  
5/10/2016Carlos AlbanEVPSell47,438$63.52$3,013,261.76149,444View SEC Filing  
5/10/2016Thomas A HurwichVPSell6,000$63.59$381,540.0068,204View SEC Filing  
5/10/2016Timothy J RichmondSVPSell21,583$63.52$1,370,952.1644,615View SEC Filing  
3/8/2016Laura J SchumacherEVPSell25,000$56.09$1,402,250.00199,238View SEC Filing  
3/1/2016Timothy J RichmondSVPSell12,866$55.05$708,273.3079,064View SEC Filing  
4/28/2015Richard A GonzalezCEOSell102,964$64.67$6,658,681.88View SEC Filing  
3/2/2015Laura J SchumacherEVPSell25,000$60.30$1,507,500.00View SEC Filing  
3/2/2015Timothy J RichmondSVPSell14,388$60.33$868,028.04View SEC Filing  
12/22/2014William J ChaseCFOSell8,495$68.00$577,660.00View SEC Filing  
3/4/2014Richard GonzalezCEOSell4,799$51.20$245,708.80395,403View SEC Filing  
3/3/2014Azita Saleki-GerhardtSVPSell2,443$50.25$122,760.7585,828View SEC Filing  
3/3/2014Carlos AlbanEVPSell2,882$50.09$144,359.38205,138View SEC Filing  
3/3/2014William ChaseCFOSell3,948$50.22$198,268.56180,068View SEC Filing  
9/17/2013Azita Saleki-GerhardtSVPSell10,473$45.84$480,082.3266,703View SEC Filing  
8/19/2013Azita Saleki-GerhardtSVPSell1,270$43.01$54,622.7064,279View SEC Filing  
8/12/2013Azita Saleki-GerhardtSVPSell8,851$44.91$397,498.4164,237View SEC Filing  
3/11/2013Edward J RappDirectorBuy2,500$37.67$94,175.00View SEC Filing  
2/4/2013Frederick H WaddellDirectorBuy2,000$37.05$74,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AbbVie (NYSE ABBV) News Headlines

Source:
DateHeadline
AbbVie Inc (ABBV) Expected to Announce Quarterly Sales of $7.60 BillionAbbVie Inc (ABBV) Expected to Announce Quarterly Sales of $7.60 Billion
www.americanbankingnews.com - February 17 at 6:06 AM
Did AbbVie, Inc. Just Become the Most Shareholder-Friendly Stock ... - Motley FoolDid AbbVie, Inc. Just Become the Most Shareholder-Friendly Stock ... - Motley Fool
www.fool.com - February 17 at 5:13 AM
AbbVies New Capital Return Program And How It Impacts Expected Total Returns - Seeking AlphaAbbVie's New Capital Return Program And How It Impacts Expected Total Returns - Seeking Alpha
seekingalpha.com - February 16 at 3:10 PM
Novartis’s Cosentyx May Emerge as a Leading Psoriasis DrugNovartis’s Cosentyx May Emerge as a Leading Psoriasis Drug
finance.yahoo.com - February 16 at 3:10 PM
Novartis’s Cosentyx Emerged as Multi-Blockbuster Therapy in 2017Novartis’s Cosentyx Emerged as Multi-Blockbuster Therapy in 2017
finance.yahoo.com - February 16 at 3:10 PM
AbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohns Disease at 52 WeeksAbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn's Disease at 52 Weeks
finance.yahoo.com - February 16 at 3:10 PM
AbbVie Inc (ABBV) Files 10-K for the Fiscal Year Ended on December 31, 2017AbbVie Inc (ABBV) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 16 at 3:10 PM
AbbVies JAK1 inhibitor upadacitinib shows durable treatment effect in mid-stage Crohns study; shares up 3%AbbVie's JAK1 inhibitor upadacitinib shows durable treatment effect in mid-stage Crohn's study; shares up 3%
seekingalpha.com - February 16 at 2:48 PM
Stock Repurchase Plan Announced by AbbVie (ABBV) Board of Directors Stock Repurchase Plan Announced by AbbVie (ABBV) Board of Directors
www.americanbankingnews.com - February 16 at 11:28 AM
AbbVie to buy back $10 billion of shares, raises dividend - Reuters - ReutersAbbVie to buy back $10 billion of shares, raises dividend - Reuters - Reuters
www.reuters.com - February 16 at 5:11 AM
Did AbbVie, Inc. Just Become the Most Shareholder-Friendly Stock in America?Did AbbVie, Inc. Just Become the Most Shareholder-Friendly Stock in America?
www.fool.com - February 15 at 10:16 PM
BMO Capital Markets Reiterates "$95.00" Price Target for AbbVie (ABBV)BMO Capital Markets Reiterates "$95.00" Price Target for AbbVie (ABBV)
www.americanbankingnews.com - February 15 at 6:20 PM
AbbVie (ABBV) Price Target Raised to $138.00AbbVie (ABBV) Price Target Raised to $138.00
www.americanbankingnews.com - February 15 at 5:06 PM
AbbVie Increases Dividend and Announces New Stock Repurchase ProgramAbbVie Increases Dividend and Announces New Stock Repurchase Program
finance.yahoo.com - February 15 at 3:10 PM
AbbVie Stock Rises After Increasing Dividend By 35%AbbVie Stock Rises After Increasing Dividend By 35%
finance.yahoo.com - February 15 at 3:10 PM
AbbVie to buy back $10 billion of shares, raises dividendAbbVie to buy back $10 billion of shares, raises dividend
finance.yahoo.com - February 15 at 3:10 PM
AbbVie stock rises after dividend boosted 35%, new $10 billion buyback programAbbVie stock rises after dividend boosted 35%, new $10 billion buyback program
finance.yahoo.com - February 15 at 3:10 PM
AbbVie Inc (ABBV) Raises Dividend to $0.96 Per ShareAbbVie Inc (ABBV) Raises Dividend to $0.96 Per Share
www.americanbankingnews.com - February 15 at 1:34 PM
AbbVie shares halted pending newsAbbVie shares halted pending news
seekingalpha.com - February 15 at 1:14 PM
AbbVie bumps dividend 35%, to buy back $10B of stockAbbVie bumps dividend 35%, to buy back $10B of stock
seekingalpha.com - February 15 at 1:14 PM
Is Now a Good Time to Buy AbbVie? -- The Motley Fool - Motley FoolIs Now a Good Time to Buy AbbVie? -- The Motley Fool - Motley Fool
www.fool.com - February 15 at 5:10 AM
Lilly's Taltz Positive in Phase III Label Expansion StudyLilly's Taltz Positive in Phase III Label Expansion Study
finance.yahoo.com - February 14 at 3:09 PM
AbbVie Appears Ready to Start a New Advance at Any TimeAbbVie Appears Ready to Start a New Advance at Any Time
finance.yahoo.com - February 14 at 3:09 PM
Inside Pfizer’s Inflammation and Immunology Portfolio Performances in 2017Inside Pfizer’s Inflammation and Immunology Portfolio Performances in 2017
finance.yahoo.com - February 14 at 3:09 PM
Is Now a Good Time to Buy AbbVie?Is Now a Good Time to Buy AbbVie?
www.fool.com - February 13 at 8:13 PM
Bristol-Myers Squibb’s Virology Products in 4Q17Bristol-Myers Squibb’s Virology Products in 4Q17
finance.yahoo.com - February 13 at 3:07 PM
AbbVie: Time To Trim Our Position? - AbbVie Inc. (NYSE:ABBV ... - Seeking AlphaAbbVie: Time To Trim Our Position? - AbbVie Inc. (NYSE:ABBV ... - Seeking Alpha
seekingalpha.com - February 13 at 5:15 AM
Is AbbVie or Vertex Pharmaceuticals the Better Buy Now? - Motley FoolIs AbbVie or Vertex Pharmaceuticals the Better Buy Now? - Motley Fool
www.fool.com - February 13 at 5:15 AM
These 3 Drugs Are Critical to AbbVie's SuccessThese 3 Drugs Are Critical to AbbVie's Success
finance.yahoo.com - February 12 at 3:07 PM
AbbVie Showcases New, Late-Breaking Investigational Data at 2018 American Academy of Dermatology (AAD) Annual MeetingAbbVie Showcases New, Late-Breaking Investigational Data at 2018 American Academy of Dermatology (AAD) Annual Meeting
finance.yahoo.com - February 12 at 3:07 PM
These 3 Drugs Are Critical to AbbVies SuccessThese 3 Drugs Are Critical to AbbVie's Success
www.fool.com - February 12 at 7:26 AM
Is AbbVie Inc’s (NYSE:ABBV) ROE Of 93.77% Sustainable?Is AbbVie Inc’s (NYSE:ABBV) ROE Of 93.77% Sustainable?
finance.yahoo.com - February 12 at 5:01 AM
Watch These Biotechs and the FDA CalendarWatch These Biotechs and the FDA Calendar
finance.yahoo.com - February 10 at 3:02 PM
Amgen’s Neulasta and Enbrel in 4Q17 and 2017Amgen’s Neulasta and Enbrel in 4Q17 and 2017
finance.yahoo.com - February 9 at 3:11 PM
What Drove Pfizer’s 4Q17 Growth?What Drove Pfizer’s 4Q17 Growth?
finance.yahoo.com - February 9 at 3:11 PM
AbbVie: Looking Very Attractive In 2018 - Seeking AlphaAbbVie: Looking Very Attractive In 2018 - Seeking Alpha
seekingalpha.com - February 8 at 3:10 PM
Imbruvica Leads in the Chronic Lymphocytic Leukemia SpaceImbruvica Leads in the Chronic Lymphocytic Leukemia Space
finance.yahoo.com - February 8 at 3:10 PM
FDA Approves Gilead (GILD) HIV Triple Therapy, Stock UpFDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up
finance.yahoo.com - February 8 at 3:10 PM
Venclexta May Prove a Novel Chemotherapy-Free Treatment OptionVenclexta May Prove a Novel Chemotherapy-Free Treatment Option
finance.yahoo.com - February 8 at 3:10 PM
ABBV to Focus on Advancing Late-Stage Immunology Research in 2018ABBV to Focus on Advancing Late-Stage Immunology Research in 2018
finance.yahoo.com - February 8 at 8:01 AM
Add These 7 GARP Stocks to Your Portfolio for Better ReturnsAdd These 7 GARP Stocks to Your Portfolio for Better Returns
finance.yahoo.com - February 7 at 3:09 PM
AbbVie Expected to Witness Strong Growth in Margins in 2018AbbVie Expected to Witness Strong Growth in Margins in 2018
finance.yahoo.com - February 7 at 3:09 PM
Why AbbVie Inc.'s Shares Rocketed 16% in JanuaryWhy AbbVie Inc.'s Shares Rocketed 16% in January
finance.yahoo.com - February 7 at 3:09 PM
Humira Will Remain a Key Growth Driver for AbbVie in 2018Humira Will Remain a Key Growth Driver for AbbVie in 2018
finance.yahoo.com - February 7 at 3:09 PM
AbbVie Inc (ABBV) Given Average Rating of "Buy" by AnalystsAbbVie Inc (ABBV) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - February 6 at 3:34 PM
Analysts’ Recommendations for AbbVie and Peers in January 2018Analysts’ Recommendations for AbbVie and Peers in January 2018
finance.yahoo.com - February 6 at 3:07 PM
AbbVies Imbruvica Gains Orphan Drug StatusAbbVie's Imbruvica Gains 'Orphan Drug' Status
finance.yahoo.com - February 6 at 3:07 PM
Centene (CNC) Beats Q4 Earnings & Revenues, Ups '18 ViewCentene (CNC) Beats Q4 Earnings & Revenues, Ups '18 View
finance.yahoo.com - February 6 at 3:07 PM
AbbVie Has Raised Its 2018 Earnings GuidanceAbbVie Has Raised Its 2018 Earnings Guidance
finance.yahoo.com - February 6 at 3:07 PM
Dont Miss Out, Act Now On AbbVie - Seeking AlphaDon't Miss Out, Act Now On AbbVie - Seeking Alpha
seekingalpha.com - February 5 at 3:08 PM

SEC Filings

AbbVie (NYSE:ABBV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AbbVie (NYSE:ABBV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AbbVie (NYSE ABBV) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.